Replies to post #210415 on Cytodyn Inc (CYDY)

[kgromax]

"Conclusions: The primary endpoint (PDFF) and secondary endpoints (cT1) were met for the 350 mg group (missing here: the 700 mg group) and moderate to severe fibro-inflammation by cT1 350 mg subgroup at baseline. The pooled 350 + 700 mg group also had significant reductions in PDFF, cT1 vs placebo. Treatment with leronlimab was well tolerated. These results are supportive of further trials with leronlimab for NASH."

LOL the 350mg group was precisely NOT a double blind trial. The group which had a double blind trial (the 700 mg group) magically DID NOT MEET its endpoints. Another failure. So easy LOL.

Usual manipulation by the company for its bagholders base, as they did for every trial before.

[BostonSportsNut]

PARTNERSHIP!!

[HyGro]

700 mg didn't do better than 350 mg?? That's disappointing. And the 350 mg. only had a 16-20% fat reduction which isn't at all competitive with leading NASH candidates that were showing 45%+ fat reduction for the same period. Nobody is going to spend the $10s of millions required for the long and expensive NASH P3. That includes a partner. These are mediocre numbers.